Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...
Fierce Biotech

Intellia races in vivo CRISPR therapy to FDA after phase 3 data paint ‘compelling’ picture

A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

Intellia seeks FDA approval for in vivo CRISPR therapy

The company's treatment for hereditary angioedema reduced attacks by 87% vs. placebo in a Phase 3 trial, clearing the way for ...

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data ...

Intellia's gene therapy for rare disease cuts swelling attacks in late-stage trial

By Kunal Das and Kamal Choudhury April 27 (Reuters) - Intellia Therapeutics said on Monday its experimental gene-editing therapy reduced the frequency of swelling attacks in patients with a rare ...
BioSpace

Intellia heads to FDA after notching first late-stage win for in vivo gene editor

With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...

CRISPR untangles five-gene protein that helps plants grow in early stages

For most of their lives, plants get their energy from photosynthesis. But during the seed to seedling stage, when they can't ...
pharmaphorum

Intellia files CRISPR drug after historic phase 3 readout

Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema ...
BioPharma Dive

Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder

The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial ...
BioSpace

Gene therapy leaders aim to help more Baby KJs with novel regulatory models

As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” ...
Labiotech.eu

Modified CRISPR tool targets Down syndrome mutation

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...